MELETPL WALE. UI/22/2001 Receipt date: 01/22/2001

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 1 6.

Co	ompl t if Known
Application Number	09/676.380
Filing Date	09/29/00
First Named Inventor	Maihle
Group Art Unit	Not yet assigned
Examiner Name	Not vet assigned
Attomey Docket Number	99-057

	U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
1150		5,708,	156	Ilekis	71=13-98		
		4,933,	294	Waterfield	06=12=90		
\vdash		5,344,	760	### NES	09-06-94	***************************************	
		5,401	538	Carney-	03-28-95		
		2,074,	(33)	<u>Narvey</u>			
 	A						
	~						
							
						~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			
		<u> </u>			<u> </u>		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials		Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevent		
	Cite No. ¹	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T 6
								T
	**********							1

								<u> </u>
			**************************************		**************************************			
		<u> </u>	·					<u> </u>

29 September 2009 /Christina Borgeest/ Date

Examiner Signature Considered *EXAMINER: Initial preference considered, whether or not citation is in conformance with MPEP 609. Draw line through cription if not in conformance and not

considered. Include copy of this form with next communication to applicant. 1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). A For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial

number of the patent document. A Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

Appro U. S. Patent and Trade o cersons are required to rescond to a collection of informaPTC/SB/088 (08-00) for use through 10/31/2002, OMB 0651-0031 mice: U.S. DEPARTMENT OF COMMERCE

less it contains a valid OMB control number

Under the Paperwork Reduction Act of

Substitute for form 14498/PTO INFORMATION DISCLOSURE

JAN 2 2 200

TATEMENT BY APPLICANT

(use as many sheets as necessary)

of 6

Complete if Known			
Application Number	09/676,380		
Filing Data	09/29/00		
First Named Inventor	Maihle		
Graup Art Unit	Not vet assigned		
Examiner Name	Not vet assigned		
Attomey Docket Number	99-057		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	20000
Examiner Initials	Cite No.¹	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
ghe.		REITER, JILL L. and MAIHLE, NITA J.; A 1.8 kb Alternative Transcript from the Human Epidermal Growth Factor Receptor Gene Encodes a Truncated Form of the Receptor; Journal; 4050-56 Nucleic Acids Research, 1996, Vol. 24, No. 20.	
A CONTRACTOR OF THE CONTRACTOR		BARON, ANDRE T., et al; Monoclonal Antibodies Specific for Peptide Epitopes of the Epidermal Growth Factor Receptor's Extracellular Domain; Journal; HYBRIDOMA, Mary Ann Liebert, Inc., Mayo Clinic Foundation; Vol. 16, No. 3, 1997.	
	A	AKJOO LEE and MAIHLE, NITA; Isolation and Characterization of Four Iternate c-erbB3 Transcripts expressed in Ovarian Cardinoma-derived Cell ines and Normal Human Tissues; Oncogene (1998) 16, 3243-3252.	-
	T C	ARON, ANDRE T.; Serum sErbB1 and Epidermal Growth Factor Levels as umor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer; ancer Epidemiology, Biomarkers and Prevention, Vol. 8, 129-137, February 299.	
	R	OWNWALD, et al; article: Close Similarity of Epidermal Growth Factor eceptor and v-erB oncogene protein sequences; NATURE, 307 (5951), 521-27 (1984).	
***************************************	U	LLRICH, et al., article; NATURE, 309, 418 (1984).	
	C	OUSSENS, et al.; article; SCIENCE, 230, 1132-1139 (1985).	•
	К	RAUS et al., article, PROC. NAT'L. ACAM. SCI. USA, 86, 9193 (1989).	
	PI	OWMAN, et al, article, PROC. NAT'L. ACAM. SCI. USA, 87, 4905 (1991).	
	1	///Christina Borgeest/ 29 September 2009)
kaminer gnature		Date Considered 30 Mal 2002	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Wasnington, DC 20231.

Unique citation designation number. 3 Applicant is to place a check mark here if English language Translation is attached.

PTC/SB/088 (08-00)

Appn or use through 10/31/2002 OM8 0851-0031

U. S. Patent and Tradamack Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no cersons are required to respond to a collection of information unless it contains a valid OM8 control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet 3 6

Complete if Kn wn			
Application Number	09/676,380		
Filing Date	09/29/00		
First Named Inventor	Maihle		
Group Art Unit	Not vet assigned		
Examiner Name	Not vet assigned		
Attorney Docket Number	99-057		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials No.1		Include name of the author (in CAPITAL LETTERS), title of the artide (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ²	
M		MAIIILE, et al; article; PROC NAT'L ACAM. SCI, 88, 1825 (1991).		
1		ILEKIS, et al, article, MOL. REPROD. DEVEL., 41, 149 (1995).		
		MERLINO, et al, article, MOL. CELL. BIOL., 5, 1722 (1985).		
		HUNTS, et al; CELL MOL. GENET., 11, 477 (1988).	-	
		PETCH et al, MOL. CELL. BIOL., 10, 2973 (1990).	-	
		McKENZIE; article; BIOCHEM, BIOPHYS. ACTA, 1072, 193 (1991).	-	
		BRANDT-RAUF; article; MUTAT. RES., 333, 203 (1995).		
- Anna Carlotte (Albert Albert		MORI et al; article; JPN. J. CANCER RES., 81, 489 (1990).		
		MEDEN et al; article, ANTICANCER RES., 17, 757 (1997).		
		HAYES et al; article; BREAST CANCER TREAT., 14, 135 (1993).	-	
		LEITZEL et al, article, J. CLIN. ONCOL., 13, 1129 (1995).	-	
		YAMANCHI, et al.; article; J. CLIN. ONCOL., 15, 2518 (1997).		
	-	PARTANEN et al., article, J. OCCUP. MED., 36, 1324 (1994).	-	
		PARTANEN et al; article; INT. J. ONCOL., 4, 1025 (1995).		
		WITTERS et al, article; CLIN. CANCER RES., 1, 551 (1995).		
. <i>V</i>		/Christina Borgeest/ za September z		

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is astimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached,

Please type a plus sign (+) inside this

Sheet

Signature

	_	-
		- 1
- 5		- 1
		- 1

PTO/SB/08B (08-00)
Appr. Pr use through 10/31/2002 OMB 0551-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resc.

Substitute for form 14498/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of 6

TOTAL TO BE CONCEDED IT OF IMPORTANCE	of different decision of take Child Control (Childing)		
C mplete if Known			
Application Number	09/676,380		
Filing Date	09/29/00		
First Named Inventor	Maible		
Group Art Unit	Not vet assigned		
Examiner Name	Not vet assigned		
Attorney Docket Number	99-057		

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ffe	-	ILEKIS, J.V., et al; article; Expression of a Truncated Epidermal Growth Factor Receptor-like Protein (TEGFR) in Ovarian Cancer; GYNECOL. ONCOL. 65: -36-41 (1997).
		XU et al; article; PROC. NAT'L ACAD. SCI., 81, 7308 (1984).
		SALOMEN et al; article; CRIT. REV. ONCOL. HEMATOL., 19, 183 (1995).
	ļ	KING et al; article; SCIENCE, 229, 974 (1985).
		HENDLER et al; article; PROC. AM. SOC. CLIN. ONCOL., 8, 223 (1989).
		VEALE et al, article, CANCER RES., 49, 1313 (1989)
		SCHLEGEL et al; article; INT. J. CANCER, 56, 72 (1994).
		NEAL, et al; article; CANCER, 65, 1619 (1990).
		MELLON et al; article; J. UROL., 153, 919 (1995).
		BERCHUCK et al; article; AM. J. OBSTET. GYNECOL., 164, 669 (1991).
		SCAMBIA et al; article; J. CLIN. ONCOL., 10, 529 (1992)
		SAMBROOK et al; article; MOLECULAR CLOSING: A Laboratory Manual, Cold Spring Harbor, NY (1989).
No.		LAWN et al; article; NUCLEIC ACIDS RES., 9, 6103 (1981)
		/ Christina Borgeest/ 29 September 2009
xaminer	1	7 / // Date C. C.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Considered

⁹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)
App Or use through 10/31/2002, OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to reso Substitute for form 1449B/PTO JAN 2 2 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known			
Application Number	09/676,380		
Filing Date	09/29/00		
First Named Inventor	Maihle		
Group Art Unit	Not yet assigned		
Examiner Name	Not vet assigned		
Attorney Docket Number	99-057		

	**********	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
MA		GOEDDEL et al, article, NUCLEIC ACIDS RES., 8, 4057 (1980).	ANALAS CONTRACTOR CONT
		ADELMAN, et al; article; DNA, 2, 183 (1983).	
		CREA, et al; article; PROC. NAT'L ACAD. SCI., 75, 5765 (1978)	
		VIERA et al; article; METH. ENZYMOL., 153, 3 (1987).	-
		STEWART et al., Solid Phase Peptide Synthesis, W.H. Freeman Co., San Francisco (1969)	+
		MERRIFIELD, J. Am. Chem. Soc., 85, 2149 (1963) "Peptide Synthesis: A Re	eview of the
		MEIENHOFER, "Hormonal Proteins and Peptides," ed. Solid Phase Method	1, 1973,
		FLICKINGER et al., Mol. Cell. Biol., 12, 883 (1992) Vol. 2, Li (ed.), Academic Press, pp	p. <u>4</u> 5-267.
		CHEN et al., Nature, 32, 820 (1987)	RECEIPER
and district		AUSUBEL et al., Curren Protocols in Molecular Biology, John Wiley & Sone NY (1994)	·
		MAIHLE et al., Mol. Cell. Biol., 8, 4868 (1988)	NO.
		WATERFIELD et al., J. Cell. Biochem., 20, 149 (1989)	
		BARON et al., October 1, 1998, A sandwich type acridinium-linked immunosorbent assay (ALISA) detects "soluble" ErbB1 (sErbB1) analogs in normal human serum; J. Immunol. Methods, 219, 23-43	
		/Christina Borgeest/ 29 September 20	09

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Onew line through citation and in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

JAN 2 2 2001

Please type a plus sign (+) inside this

PTC/S8/088 (08-00)
App of for use through 10/31/2002, OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

inder the Paperwork Reduction Act of 1995, no persons are required to reapond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 14498/PTO Application Number 09/676,380 INFORMATION DISCLOSURE Filling Date 09/29/00 STATEMENT BY APPLICANT First Named Inventor Maihle Group Art Unit Not Yet Assigned (use as many sheets as necessary) Examiner Name Not Yet Assigned Attomey Docket Number Sheet of 6 99-057

	~	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	2000000000000000000000000000000000000
Examiner Initlals	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	ls
91		CHEN et al., 1989; a.k.a. pXEGFR, Opresko et al., 1995	
1		MOSCOVICI et al., 1977; ATCC	

			The state of the s
		· ·	
			·
		/Christina Borgeest/ 29 Septem	iber 20
xaminer ignature		Date Considered 3 4 1 cm	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in the considered include copy of this form with next communication to applicant.

Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.